 |
| |
 |
| |
 |
| |
 |
| |
 |
_____________________________________________________________________________________________________________________
© 2005-9 All Rights Reserved. NOD Pharmaceuticals, Inc.
| Nodlin |
NOD Pharmaceuticals, Inc. is developing the leading product candidates in China via its wholly
owned subsidiary Biolaxy. Oral insulin and exenatide are the leading candidates under development.
owned subsidiary Biolaxy. Oral insulin and exenatide are the leading candidates under development.
Products
Insulin is the standard treatment for diabetic patients and requires multiple daily injection, often for
life. Nodlin is an oral insulin formulation in a capsule form based on enteric coated insulin
nano-particles. Nodlin is indicated for basal insulin supplementation.
life. Nodlin is an oral insulin formulation in a capsule form based on enteric coated insulin
nano-particles. Nodlin is indicated for basal insulin supplementation.
 |  |  |
| Product Preclinical | P1 | P2 | P3 | NDA | Market |
| N |
| Nodlin |
| N |
| Nodexen |
| Nodexen |
Exenatide is a GLP-1 agonist for treating diabetes that requires twice daily injections. Nodexen is
oral exenatide formulation in a capsule form based on enteric coated interferon nano-particles. This
product may reduce side effects and significantly improve efficacy over conventional injections.
oral exenatide formulation in a capsule form based on enteric coated interferon nano-particles. This
product may reduce side effects and significantly improve efficacy over conventional injections.
NOD
Pharmaceuticals, Inc.
| Innovation Delivered |
| | |